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Background: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with
oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent
rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear
promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The
goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR
treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions,
compared to patients who receive standard of care treatment alone.
Methods: After stratification by the number of metastases (1-3 vs. 4-5), patients will be randomized between Arm
1: current standard of care treatment, and Arm 2: standard of care treatment + SABR to all sites of known disease.
Patients will be randomized in a 1:2 ratio to Arm 1:Arm 2, respectively. For patients receiving SABR, radiotherapy
dose and fractionation depends on the site of metastasis and the proximity to critical normal structures. This study
aims to accrue a total of 99 patients within four years. The primary endpoint is overall survival, and secondary
endpoints include quality of life, toxicity, progression-free survival, lesion control rate, and number of cycles of
further chemotherapy/systemic therapy.
Discussion: This study will provide an assessment of the impact of SABR on clinical outcomes and quality of life, to
determine if long-term survival can be achieved for selected patients with oligometastatic disease, and will inform
the design of a possible phase III study.
Trial registration: Clinicaltrials.gov identifier: NCT01446744
Keywords: Oligometastases, Stereotactic radiotherapy, Quality of life, Cancer, SurvivalBackground
The oligometastatic disease state was first defined in
1995 and refers to an stage of disease where cancer has
spread beyond the site of origin, but is not yet widely
metastatic [1]. In such a state of limited metastatic dis-
ease burden, it is hypothesized that eradication of all sites
of metastatic disease could result in long-term survival,* Correspondence: david.palma@uwo.ca
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reproduction in any medium, provided the oror even cure, in a subgroup of patients [2]. Ablation of
metastatic deposits can be achieved surgically, or through
stereotactic ablative radiotherapy (SABR), a new radio-
therapy technology that delivers very large, hypofractio-
nated doses of radiotherapy with high precision to small
tumor targets, with high rates of local control.
Clinical evidence to support the presence of an oligo-
metastatic state is emerging in both the surgical and
SABR literature, for several tumor types. In a study of
over 5200 patients with lung metastases who underwent
surgical resection, a 5-year survival of 36% was reportedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Palma et al. BMC Cancer 2012, 12:305 Page 2 of 8
http://www.biomedcentral.com/1471-2407/12/305in patients who achieved a complete resection, much
higher than would be expected for many patients with
disseminated stage IV disease [3]. Similarly, in patients
treated with SABR for 1-3 lung metastases from a variety
of primary tumors, local control with SABR was 96% at
2-years, and 2-year survival was 39% [4]. Long-term sur-
vival has been demonstrated in patients treated for oligo-
metastases with surgery or SABR at several other tumor
sites, including liver, brain, bone, and adrenal metastases
[2,5-8]. However, even after such treatment, the risk of
further metastases after ablative treatment is high, up to
60-80% in some studies [4,5]. In some cases, SABR can
be used for further salvage at newly progressive sites [9].
Despite the apparent achievement of long-term sur-
vival with ablative treatment for oligometastatic disease,
the level of evidence to support such treatments is weak
in many cases, often based on single-arm studies without
appropriate controls [10]. Patients included in such
reports are highly selected, based on good performance
status and slow pace of tumor progression. It has been
suggested that the long-term survival achieved with
treatment of oligometastases is a result of the selection
of fit patients with very slow-growing tumors, rather
than the result of treatment intervention [11].
Randomized trials are therefore necessary to establish
the utility of ablative treatment of oligometastatic disease
[10,12], but such randomized trials are rare. One such
completed randomized trial, Radiation Therapy and On-
cology Group Trial 9508, compared whole brain radio-
therapy (WBRT) with WBRT + stereotactic treatment for
patients with 1-3 brain metastases, and found an overall
survival advantage only in patients with a single metasta-
sis and those patients in the most favorable baseline re-
cursive partitioning analysis (RPA) prognostic group [13].
Patients with inferior baseline prognostic factors did not
achieve a survival benefit from stereotactic treatment. At
least one other randomized trial investigating the oligo-
metastatic paradigm has recently opened: in 2010, the
Pulmonary Metastasectomy in Colorectal Cancer (Pul-
MiCC) trial was launched, comparing metastatectomy
with best supportive care in patients with pulmonary me-
tastases from colorectal cancer [14].
It is unclear if all patients with oligometastatic disease
benefit from SABR, in terms of improved local control,
improved survival or improved quality of life. Although
SABR generally results in ablation of each metastatic tar-
get, patients remain at high risk of further metastatic
progression. Results from SABR for treatment of oligo-
metastases in published studies appears promising, but
these promising results may be due to patient selection,
rather than treatment intervention, and are based on com-
parisons with historical controls. The benefit of comprehen-
sive treatment of oligometastases can only be demonstrated
conclusively in the context of a randomized trial.Methods/design
This study is designed as a randomized phase II study.
Patients will be randomized between current standard of
care treatment (Arm 1) vs. standard of care treatment +
SABR (Arm 2) to sites of known disease (Figure 1).
Patients will be randomized in a 1:2 ratio to Arm 1 vs.
Arm 2, respectively. This study has been approved by
the Ontario Cancer Research Ethics Board (#11-030), in
compliance with the Helsinki Declaration.
The randomized phase II design is required for 3 rea-
sons: First, the randomization will provide an appropri-
ate control group to serve as a comparator for the
experimental arm. Historical or contemporaneous non-
randomized controls would not be appropriate due to
the multitude of biases that could be introduced by pa-
tient selection and other confounders. Second, a small
sample size will allow for adequate power to assess for
an early overall survival difference, quality of life, and to
evaluate toxicity in the SABR arm. Third, the results will
allow for a decision as to whether a multi-institutional
phase III trial is warranted, and inform the design of
such a trial.
Objectives
To assess the impact of a comprehensive oligometastatic
SABR treatment program on overall survival and quality
of life in patients with up to 5 metastatic cancer lesions,
compared to patients who receive standard of care treat-
ment alone.
Primary endpoint
 Overall Survival Defined as time from randomization to death
from any causeSecondary endpoints
 Quality of life Assessed with the Functional Assessment of
Cancer Therapy: General (FACT-G)
 Toxicity
 Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
for each organ treated (e.g. liver, lung, bone)]
 Progression-free survival
 Time from randomization to disease progression
at any site or death
Figure 1 Study design. Patients with be randomized in a 1:2 ratio between Arm 1 (Standard of care) vs. Arm 2 (SABR).
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 Number of cycles of further chemotherapy/systemic
therapy
Inclusion criteria
 Age 18 or older
 Willing to provide informed consent
 Histologically confirmed malignancy with metastatic
disease detected on imaging. Biopsy of metastasis is
preferred, but not required.
 ECOG performance status 0-1
 Controlled primary tumor○ defined as: at least 3 months since original tumor
treated definitively, with no progression at
primary site
 All sites of disease can be safely treated based on
criteria below
 Maximum 3 metastases in any single organ system
(i.e. lung, liver, brain, bone), and the total number of
metastases must be 5 or less. For example, a patient
with two liver metastases and two lung metastases is
eligible. Life expectancy >6 months
 Not a candidate for surgical resection at all sites:
surgery to all sites not recommended by
multidisciplinary team, or unfit or declining
surgery
 Prior chemotherapy allowed but no
chemotherapy (cytotoxic or molecularly targeted
agents) therapy 4 weeks prior to first fraction of
radiotherapy, during radiotherapy, or for two
weeks after last fraction. Hormonal therapy is
allowed.
 Patients with metastases that have been previously
treated (e.g. prior resection, RFA or radiotherapy):
○ If that previously treated metastasis is controlled
on imaging, the patient is eligible for this study
and that site does not need treatment
○ If that previously treated metastasis is NOT
controlled on imaging:▪ If the previous treatment was surgery, the
patient is eligible if that site can be treated by
SABR
▪ If the previous treatment was radiotherapy or
RFA, the patient is ineligibile.
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or radiotherapy departmental quality-assurance
rounds, with consensus opinion that entry into the
study is appropriate.Exclusion criteria
 Serious medical comorbidities precluding
radiotherapy
 Bone metastasis in a femoral bone
 Patients with 1-3 brain metastasis and no disease
elsewhere (these patients should not be randomized
but treated with stereotactic radiotherapy as per
results of randomized trials)
 Prior radiotherapy to a site requiring treatment
 Complete response to first-line chemotherapy
(i.e. no measurable target for SABR)
 Malignant pleural effusion
 Inability to treat all sites of active disease
 Clinical or radiologic evidence of spinal cord
compression OR tumor within 3 mm of spinal cord
on MRI.
 Dominant brain metastasis requiring surgical
decompression
 Pregnant or lactating womenEvaluation and randomization
Prior to randomization, a complete history and physical
examination by the treating radiation oncologist is
required. Histologically confirmation of malignancy is
required, with metastatic disease detected on imaging.
Biopsy of metastasis is preferred, but not required.
Patients must be restaged within 12 weeks prior to
randomization, including brain CT or MRI imaging (for
tumor sites with propensity for brain metastasis); and
CT neck/chest/abdomen/pelvis with bone scan. PET-CT
is only required for specific evidence-based indications,
as defined by the Ontario Health Insurance Program,
and in such cases the CT neck/chest/abdomen/pelvis
and bone scan are not required. For other indications, at
the discretion of the treating oncologists, PET-CT scans
may be done but are not required. MRI spine is required
for patients with vertebral or paraspinal metastases.
Patients with liver metastases are also required to have
adequate liver function tests (AST, ALT, GGT, alkaline
phosphatase). A negative pregnancy test is required for
women of child-bearing age.
The study will employ a 1:2 randomization between
Arm 1:Arm 2 (Figure 1). The sample size allows for one
stratification factor at randomization: number of meta-
static sites (1-3 vs. 4-5). Randomization will occur in
permuted blocks of nine.Interventions
Arm 1
Radiotherapy for patients in the standard arm should
follow the principles of palliative radiotherapy as per the
individual institution, with the goal of alleviating symp-
toms or preventing imminent complications. Patients in
this arm should not receive stereotactic doses or radio-
therapy boosts.
Treatment recommendations for patients in Arm 1 are
as follows: For brain metastases, whole brain radiother-
apy (i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions); for
lung metastases, palliative radiotherapy as per 2011 con-
sensus guidelines (i.e. 8 Gy in 1 fraction, 20 Gy in 5 frac-
tions, 30 Gy in 10 fractions)[15]; for bone metastases,
palliative radiotherapy as per 2011 consensus guidelines
(i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 frac-
tions, 30 Gy in 10 fractions)[16]; for liver metastases, 20
Gy in 5 fractions if standard institutional practice.
For Arm 1, Treatment planning is to be done using
CT simulation or conventional simulation (fluoroscopy)
as per individual institutional practice. Simple beam
arrangements, such as parallel opposed beams, are
favored wherever possible.
Arm 2
For Arm 2, all treatments in this study are based on
current protocols in clinical use at the LRCP and VUmc
for treatment of lung [17], liver [18], brain [19,20], and
spinal column [21] metastases. The guiding principle for
radiotherapy is to achieve disease control but to
minimize any potential adverse impact on quality of life.
Concurrent chemotherapy or targeted therapy at the
time of radiotherapy is not permitted within the 4 weeks
prior to SABR. Hormone therapy is permitted.
Doses and fractionations by tumor site are shown in
Table 1. Treatment will be setup using reproducible
positioning, verified using an on-line protocol, for all
patients in this study. Immobilization may include a cus-
tom immobilization device, such as thermoplastic shell
or Vac-lokTM bag, as per individual institutional practice
when delivering SABR. Some centers do not use
immobilization devices and have demonstrated high
degrees of accuracy; this is acceptable in this study.
All patients in Arm 2 will undergo planning CT simu-
lation. 4-dimensional CT will be used for tumors in the
lungs or liver. Axial CT images will be obtained
throughout the region of interest. For all lesions, the
gross tumor volume (GTV) will be defined as the visible
tumor on CT and/or MRI imaging +/- PET. No add-
itional margin will be added for microscopic spread of
disease, consistent with current protocols (i.e. Clinical
Target Volume [CTV] = GTV). For vertebral lesions, the
entire vertebral body may be considered the CTV, as per
institutional practice. A Planning Target Volume (PTV)
Table 1 Dose and fractionations by site
Tumor Location Description Total Dose (Gy) Number of
fractions
Dose per
fraction (Gy)
Frequency
Lung Tumors 3 cm or less surrounded
by lung parenchyma
54 3 18 Every second day
Abutting chest wall or >3 cm 55 5 11 Every second day
Within 2 cm of mediastinum or
brachial plexus
60 8* 7.5 Every second day
Bone Any bone except femur 35 Gy 5 7 Daily
Vertebral body: additional options 16-20 Gy OR 1 16-20 Single dose
30 Gy 3 10 Every second day
Brain Metastases If whole brain treated, then
simultaneous
boost to each lesion
40 Gy to metastases
20 Gy whole brain (optional)
5 8 Gy to lesion
4 Gy WBRT
Daily
Liver LRCP site: Dose is based on
calculated normal tissue
probability of <5%
Every second day
Other sites 45-60 3-8 7.5-15 Every second day
Adrenal 60 Gy 8 7.5 Every second day
*If esophageal dose constraints cannot be met, 12 fractions should be used.
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disease, immobilization, and institutional set-up accur-
acy: 2 mm margins may be used for spinal stereotactic
treatments, 2 mm for brain tumors, and 5 mm for other
sites. Organs at risk visible in the planning CT scan will
be contoured. Constraints for 1-, 3- and 5-fraction regi-
mens are taken from Timmerman et al. 2008 [22],
whereas equivalent doses were calculated for other frac-
tionation schemes.
For spinal lesions, a pre-treatment MRI is required to
assess the extent of disease and position of the cord.
This must be fused with the planning CT scan. A Plan-
ning Organ at Risk Volume (PRV) expansion of 2 mm
will be added to the spinal cord, and dose constraints for
the spinal cord apply to this PRV.
It is strongly recommended that dose constraints not
be exceeded. If a dose constraint cannot be achieved due
to overlap of the target with an organ at risk, the frac-
tionation can be increased or the target coverage com-
promised in order to meet the constraint. It is strongly
recommended that in cases where the target coverage is
compromised in order to meet the constraint, the mean
dose delivered to the GTV should be at least 80% of the
nominal dose in Table 1. All such cases of dose reduc-
tion or target coverage compromise must be approved
by the local PI prior to treatment. For vertebral tumors,
an adequate PRV of 2 mm must be added to the spinal
cord, and the dose constraints apply to this PRV.
For lung tumors, doses are prescribed to approxi-
mately the 80% isodose line surrounding the PTV,
resulting in a hotspot of 120-140%; the latter should fall
within the GTV. 95% of the PTV should be covered bythe prescription dose, and 99% of the PTV should be
covered by 90% of the prescription dose.
For other tumor sites, doses are prescribed to approxi-
mately the 100% isodose level and 95% of the PTV
should receive 95% of the prescription dose. Doses will
be corrected for tissue inhomogeneity. Several non-
overlapping 6/10 MV beams (on the order of 7-11
beams) or 1-2 VMAT arcs combined possibly with a few
non-coplanar beams is recommended. Non-coplanar
beams can be used to reduce 50% isodose volume for
un-gated treatments. Coplanar beams are recommended
for respiratory-gated treatment.
For lung or liver metastases, each metastasis can be
treated with a separate isocenter if metastases are well-
separated. Since most metastases are treated every other
day (Table 1), when two metastases are treated, these
can be done on alternating days to reduce the daily time
required on the linear accelerator (e.g. Monday/Wed/
Friday for one target, and Tues/Thurs/Mon for another).
For brain metastases, all the metastases should be trea-
ted at the same time. For bone metastases, if multiple
metastases can be imaged and localized at the same
time, they can be treated at the same time, otherwise,
they can be treated on alternate days.
The sequencing of tumor sites is at the discretion of
individual physicians, but in general should begin with
the brain, due to risks associated with progression, fol-
lowed thereafter by liver, lung, and bone.
Quality assurance (Arm 2)
In order to ensure patient safety and effective treatment de-
livery, a robust quality assurance protocol is incorporated.
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patient:
 Prior to treatment, each patient must be discussed
at quality assurance (QA) rounds.
 All radiotherapy plans must meet target dose levels
for organs at risk (Tables 2). Prior to plan approval,
the dose to each organ at risk must be verified by
the physicist or treating physician. It is strongly
recommended that dose constraints not be
exceeded.
 All dose delivery for intensity-modulated plans
(including arc-based treatments) will be confirmed
before treatment by physics staff.
 Cone-beam CT (CBCT) will be used to verify
patient positioning immediately prior to treatment.
Ideally, direct tumour localization should be
performed for stereotactic treatments of soft tissues.
For gated SABR treatments, direct tumour
localization will be performed by matching the
tumour position with the ROI defined by
IGTV_CBCT. This will be followed by a gated
2D-kV in the AP plane to verify the gating window.
In the absence of direct tumour localization, reliable
soft tissue surrogates are recommended. A repeat
CBCT will be done 25 minutes after the first, if
delivery requires more than 25 minutes. A final
CBCT may be done after completion of treatment.Quality assurance for centres joining study
Prior to opening the study, each participating research
centre will be required to send to one of the Principal
Investigators a mock treatment plan for the anatomic
sites that will be treated (e.g. lung, brain, liver, ad-
renal), to ensure that the treatment plans are designed
in compliance with the protocol. The principal investi-
gators will provide pertinent CT datasets. Each partici-
pating research centre can choose which tumor sites
will be treated at their individual centre (i.e. some cen-
tres may only choose to treat a subset of the eligible
metastatic sites).Table 2 Follow-up schedule
Before
Treatment
Years
Every
History and Physical X X
Baseline staging investigations (see text) X
CT head, chest, abdomen, pelvis
Bone Scan
Toxicity Scoring X
FACT-G QOL scoring X XChemotherapy
Patients treated with prior chemotherapy are eligible
for this study, however, no chemotherapy agents (cyto-
toxic, or molecularly targeted agents) are allowed
within the period of time commencing 4 weeks prior
to radiotherapy (conventional or SABR) lasting until 2
weeks after the last fraction. Hormonal therapy is
allowed. Use of chemotherapy schemes containing po-
tent enhancers of radiation damage (e.g. gemcitabine,
adriamycin) are discouraged within the first month
after SABR.Further radiotherapy for progressive disease at new
metastatic sites
Patients in Arm 1 who develop new, untreated meta-
static deposits can receive palliative radiotherapy for any
new such sites of progression. Patients in Arm 2 who
develop new, untreated metastatic deposits should be
considered for SABR at those sites, if such deposits can
be treated safely with SABR, and if the treating institu-
tion offers SABR for that body site. If SABR is not pos-
sible, then palliative RT can be delivered if indicated.Follow-up
Patients will be seen every three months post-
randomization for the first two years, and every six
months until 5 years after treatment (Table 2). At each
visit, a history and physical examination will be con-
ducted by the oncologist, and CTC-AE toxicities
recorded. The FACT-G Quality of life questionnaire is to
be completed at each visit.
CT head, chest, abdomen and pelvis, and bone scans
will be repeated at 3 and 6 months, then every six
months. Patients randomized to Arm 2 will be consid-
ered SABR for salvage if new sites of disease develop.
Additional Imaging or laboratory investigations should
be carried out at the discretion of the oncologist, based
on findings in the history or physical, and additional
treatment (e.g. further chemotherapy) is at the discretion
of the oncologists.1-2 Years 3-5
3 months Month 3, 6, 12, 18 and 24 Every 6 months
X
X X
X X
X
X
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Overall survival will be measured as time until death
from any cause, and progression-free survival as time to
either progression or death, whichever occurs first. Le-
sion response will be evaluated in this study using the
international criteria proposed by the Response Evalu-
ation Criteria in Solid Tumors (RECIST) Committee
(http://ctep.info.nih.gov/guidelines/recist.html). The sum
of the longest diameter (LD) for all target lesions will be
calculated and reported as the baseline sum LD. The
baseline sum LD will be used as reference by which to
characterize the objective tumor response.
Statistical analysis
Sample size
This study will employ a randomized phase II design, to
conduct a preliminary and non-definitive randomized
comparison between the control and experimental arms.
The study will aim to detect a signal in improved overall
survival that would be used to design a phase III study
to definitely compare survival outcomes between the
two groups. The study will therefore be designed with
alpha = 0.20 and beta = 0.20 (as recommended for phase
II randomized studies [23]). It is estimated that the me-
dian survival of the control group after randomization in
this study will be 9 months.
There will be a 1:2 randomization between Arm 1 and
Arm 2. In order to detect a 6-month improvement in
median survival from 9 months to 15 months with
SABR, a total of 93 patients (31 in Arm 1 and 62 in Arm
2) will be needed. Assuming a 5% rate of loss to follow-
up, a total of 99 patients will be accrued (33 in Arm 1
and 66 in Arm 2). The study projects accrual over 48
months with 12 months of additional follow-up. Accrual
targets are as follows: 20 patients in year 1, and 25-30
patients in years 2, 3, and 4.
Data analysis
Patients will be analyzed in the groups to which they are
assigned (intention-to-treat).
Primary endpoint
Survival will be calculated using the Kaplan-Meier
method with differences compared using the stratified
log-rank test. Pre-planned subgroup analysis will occur
based on stratification variables. A Cox multivariable re-
gression analysis will be used to determine baseline fac-
tors predictive of survival and allow for assessment of
time to failure data important in this patient group.
Secondary endpoints
Quality of life at 6 months will be measured using
FACT-G scores, with differences between groups tested
using the Student’s t-test. Differences in rates of grade 2or higher toxicity between groups will be tested using
the Fisher’s Exact Test. Differences in progression free
survival will be tested using the stratified log-rank test.
Differences in the number of cycles of further chemo-
therapy/systemic therapy will be tested using the Stu-
dent’s t-test.
Data safety monitoring committee
The DSMC will meet annually after study initiation and
after 50 patients are accrued to review toxicity out-
comes. If any grade 3-5 toxicity is reported, the DSMC
will review the case notes to determine if such toxicity is
related to treatment. If the DSMC deems that toxicity
rates are excessive (>25% grade 3 toxicity, or >5% grade
4 or 5 toxicity), then the DSMC can, at its discretion,
recommend cessation of the trial, dose adjustment, or
exclusion of certain treatment sites that are deemed as
high-risk for complications.
The DSMC will conduct one interim analysis once 50
patients are accrued. For this analysis, the DSMC will be
blinded to the identity of each treatment arm, but OS
data will be presented for each arm. The DSMC will rec-
ommend stopping the trial if there is an OS difference
that is statistically significant with a threshold of
p < 0.001 using the log-rank test. Furthermore, if the
median OS among all patients is substantially different
than estimated in the sample size calculation, the DSMC
can recommend increasing or decreasing the target ac-
crual in order to maintain statistical power.
Discussion
Although the aggressive treatment of patients with oligo-
metastatic disease has become more common over the
last decade [24], considerable equipoise still exists as to
whether such aggressive treatments improve overall sur-
vival, or whether the long-term survival seen in single-
arm studies is due to patient selection and treatment of
slow-growing, favorable tumors [25]. Although SABR
and surgical resection of oligometastases are generally
safe, there is a risk of toxicity, and a small risk of
treatment-related mortality [26,27]. Since patients with
metastatic disease have traditionally been considered to
be best served by palliative treatments, it is incumbent
upon physicians to demonstrate that the escalation of
treatment (with attendant risks of side effects or compli-
cations) is associated with gains in survival and/or qual-
ity of life.
This multicenter, international study aims to accrue 99
patients and aims to provide preliminary evidence to as-
sess the impact of a comprehensive oligometastatic
SABR treatment program on overall survival and quality
of life. Data from this study may be used to inform the
design of a phase III study, and will lead to a better
understanding of the oligometastatic paradigm.
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